Following the recent retirement of Jonathan Javitt in March, Robert Besthof, Head of Operations and Chief Commercial Officer, has taken over as interim chief executive officer of NRx Pharmaceuticals. He said there was a need for a CEO to be based in the U.S. alongside the rest of the team.
Synexa Life Sciences (Synexa), a global leader in clinical biomarker and bioanalytics research services, recently secured 5,000 square feet of lab space in Rockville, Maryland. The new lab will be located within Inotiv, Inc.’s (Inotiv) Rockville site and is part of a new partnership between Synexa and Inotiv, a leading contract research organization.
NextCure, an emerging global leader in developing novel immunomedicines to treat cancer and other immune-related diseases, was recently featured on Prince George’s County Economic Development Corporation’s (PGCEDC) Business Spotlight video series.
Over a period of four days, life sciences companies from across the globe will descend on San Diego for the annual Biotechnology Innovation Organization (BIO) meeting. Multiple companies from Maryland, as well as the Department of Commerce, will be among them, showcasing the strength of the BioHealth Capital Region.
Today, a host of life sciences companies are utilizing gene therapy as a tool to find a cure for HIV. When discussing an HIV cure, there are two different possible targets: a “functional cure” where HIV is not eradicated but rather totally controlled without further ART treatment and a “sterilizing cure” that eliminates HIV completely from the body.
Enter Nucleate, the student-run non-profit organization developing future leaders in the life sciences industry by educating current academic trainees. It provides free programs that democratize biotech education and helps identify and support talent in life sciences and biotech. They also work to initiate new intellectual communities, build bridges within the biotech ecosystem and increase the quality and quantity of life science technologies spinning out in academic labs. Most importantly, Nucleate is building a community that focuses on outreach, diversity, equity, and inclusion to make biotech/life science accessible.
Like many other industry sectors, the bioscience space has been slow to embrace the digital future. Investing in and building out an integrated, enterprise-wide digital platform always played second fiddle to funding R&D, hiring, manufacturing and the commercial function. A Deloitte “Perspectives” piece perhaps framed the current state of digital transformation in the life sciences best, suggesting that organizations need to move “…from merely doing digital to being digital” or risk irrelevancy.
Center for Breakthrough Medicines Beats Back on the 2022 Biotech Bear Market with Rapid Hiring and Expansion￼
Audrey Greenberg, co-founder of CBM and also the executive director of The Discovery Labs, said the successful growth seen at CBM is a testament to the great company culture the organization has built since its founding in 2019. Among the hires in the first quarter of this year is John Lee, PhD, the new Vice President and Head of Cell Therapy. Lee, an accomplished CAR-T immunobiologist, was hired in March to lead cell therapy programs at CBM. Prior to joining CBM, Lee established the Cell Therapy Platform team at Janssen Pharmaceuticals. He also served as head of Oncology Cell Therapy at GlaxoSmithKline.
One of the leaders in the DE&I biotech space has been Gilead, the parent company of Kite, which launched a robust, action-oriented DE&I initiative in 2019. Gilead and Kite have made concerted efforts to improve workplace culture for underrepresented groups; they currently have programs focused on advancing black leadership, developing diverse talent, building diversity representation goals, establishing pay equity, and working with its partners on DE&I efforts.
An impact investor can be an individual or investment fund that has co-equal primary goals: to make money and foment positive social change that can last. In some ways, impact investors are “social VCs”—they fund projects and companies that can create positive, measurable impact for the greater good of humanity. Unlike traditional VC investment strategies that tend to take a high risk, high reward approach, impact investing generally focuses on lower risk, more modest or conservative financial investments that yield the most possible good for people and communities.